Skip to main content

Table 3 Persistence breakdown by symptoms, adverse events, drug use, knowledge of family members about Wilson disease (WD) and position towards treatment

From: Persistence with treatment for Wilson disease: a retrospective study

DescriptionPersistentNon-persistentP value for persistent vs. non-persistent
Symptoms, n (%)
 Hepatic (n = 79)57 (45.2)22 (50.0)0.59
 Neurological (n = 91)69 (54.8)22 (50.0) 
Gender, n (%)
 Male (n = 77)53 (42.1)24 (54.5)0.15
 Female (n = 93)73 (57.9)20 (45.5) 
Adverse events, n (%)
 Yes (n = 61)43 (34.1)18 (40.9)0.42
 No (n = 109)83 (65.9)26 (59.1) 
Drug used, n (%)
 D-penicillamine (n = 76)57 (45.2)19 (43.2)0.81
 Zinc sulphate (n = 94)69 (54.8)25 (56.8) 
Treatment duration, mean ± SD, years11.7 ± 3.211.6 ± 3.00.81
Educational level, n (%)
 Vocational education29 (23.0)11 (25.0) 
 Upper secondary/post secondary51 (40.5)27 (61.4)0.01
 Higher education46 (36.5)6 (13.6) 
Family knowledge about WD, n (%)
 Minimal4 (3.2)4 (9.1) 
 Little21 (16.7)12 (27.3)0.14
 Moderate42 (33.3)12 (27.3) 
 Good59 (46.8)16 (36.4) 
Family position towards treatment, n (%)
 Negative00< 0.001
 Neutral16 (12.7)18 (40.9) 
 Supportive110 (87.3)26 (59.1) 
  1. SD standard deviation